TriSalus Announces CMS Reimbursement for TriNav Infusion System

December 26, 2023—TriSalus Life Sciences Inc. recently announced that the Centers for Medicare & Medicaid Services (CMS) has created a New Technology Healthcare Common Procedure Coding System (HCPCS) code for procedures involving the company’s TriNav infusion system. TriSalus is an oncology company integrating its delivery technology with immunotherapy to treat patients with liver and pancreatic tumors.

According to the company, the new code, HCPCS C9797, has been assigned to the Ambulatory Payment Classification 5194—Level 4 Endovascular Procedures. The code may be reported by hospital outpatient departments and ambulatory surgical centers. The code will become effective on January 1, 2024.

TriSalus’ TriNav is a flexible, ultra-thin therapy delivery system with SmartValve technology. SmartValve is a self-expanding, nonocclusive one-way dynamic microvalve that opens and closes in synchrony with the patient’s heart to modulate pressure and flow. This system uses the pressure-enabled drug delivery approach and has demonstrated the ability to overcome intratumoral pressure in solid tumors and potentially improve distribution and penetration of therapy during transcatheter arterial chemoembolization and transcatheter arterial radioembolization procedures, advised the company.